Does Landiolol improve outcomes in Septic Shock? Insights from JAMA study
A new study published in JAMA has found that the beta-blocker landiolol does not improve outcomes in patients with septic shock. The study was stopped early due to a signal of possible harm, with mortality rates higher in the landiolol group than in the standard care group.
The study involved 126 patients with septic shock who were randomized to receive either landiolol infusion or standard care. The primary outcome was the mean Sequential Organ Failure Assessment (SOFA) score from randomization through 14 days. Secondary outcomes included mortality at days 28 and 90 and the number of adverse events in each group.
There was no difference in the mean SOFA score between the two groups. Mortality at day 28 was 37.1% in the landiolol group and 25.4% in the standard care group, and mortality at day 90 was 43.5% in the landiolol group and 28.6% in the standard care group.
The authors of the study conclude that landiolol should not be used for managing tachycardia among patients treated with norepinephrine for established septic shock.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.